StockNews.AI
NYXH
StockNews.AI
181 days

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

1. Nyxoah launched Genio system in the Middle East for OSA treatment. 2. First implant performed at Saudi German Hospital in Dubai, UAE. 3. Genio provides an alternative to CPAP for OSA patients. 4. Genio is the first neurostimulation therapy for OSA in the region. 5. Positive clinical evidence supports Genio's adoption and expansion.

8m saved
Insight
Article

FAQ

Why Bullish?

The launch of Genio in new markets can drive revenue growth and expand market share, akin to previous successful product launches in new regions that positively impacted stock prices.

How important is it?

This commercial launch is a significant milestone that showcases Nyxoah's innovation, potentially influencing investor sentiment and stock valuation.

Why Long Term?

Establishing a presence in the Middle East should yield long-term revenue benefits, as seen in other med-tech companies expanding into emerging markets.

Related Companies

OSAMEDNYSE
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates Mont-Saint-Guibert, Belgium – February 19, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in the Middle East, marked by the first successful Genio implant performed at Saudi German Hospital, Dubai – United Arab Emirates. The first patient was successfully implanted by Dr. Ahmed Yassin Bahgat, Consultant Otolaryngologist at Saudi German Hospital. Reflecting on this milestone, Dr. Bahgat stated: "We are honored to be the first hospital in the UAE, as well as the Middle East and Africa, to offer Genio to our OSA patients. Genio is an innovative, clinically proven, and smart therapy designed to effectively treat individuals with Obstructive Sleep Apnea who are unable to tolerate CPAP." Olivier Taelman, CEO of Nyxoah, added: “The commercial launch of Genio in the UAE marks an historic milestone as the first-ever neurostimulation therapy for Obstructive Sleep Apnea in the region. We are proud to bring this groundbreaking, patient-centric solution to the Middle East, offering new hope to patients who cannot tolerate CPAP. With strong clinical evidence and growing global adoption, we remain committed to expanding access to Genio and transforming the treatment of OSA worldwide.” About NyxoahNyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden. Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval. Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States. FORWARD-LOOKING STATEMENTS Certain statements, beliefs and opinions in this press release are forward-looking, reflecting Nyxoah's current expectations and beliefs regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and potential receipt of FDA approval and entrance into the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of Nyxoah’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that Nyxoah files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, Nyxoah expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither Nyxoah nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts: NyxoahJohn Landry, CFOIR@nyxoah.com For MediaIn Belgium/FranceBackstage Communication – Gunther De Backergunther@backstagecom.be In International/GermanyMC Services – Anne Henneckenyxoah@mc-services.eu ENGLISH_Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in UAE

Related News